Health state utilities for non small cell lung cancer - Health and Quality of Life Outcomes

Precious metals are not just ornaments; they are also important components of pharmaceutical products, such as antitumour cisplatin. Recently, the search for alternatives with improved activity has begun to focus on gold. In the journal Angewandte Chemie's International Edition, a French research team has now published the first study on [...]

Health state utilities for non small cell lung cancer - Health and Quality of Life Outcomes

Existing reports of utility values for metastatic non-small cell lung cancer (NSCLC) vary quite widely and are not all suitable for use in submissions in the UK. The aim of this study was to elicit UK societal based utility values for different stages of NSCLC and different grade III-IV toxicities commonly associated with chemotherapy treatments. Toxicities included neutropenia, febrile neutropenia, fatigue, diarrhoea, nausea and vomiting, rash …

JCI ACAT1 regulates tertiary lymphoid structures: A target for enhancing immunotherapy in non–small cell lung cancer

Non–small cell lung cancer (NSCLC), the most common type of lung cancer, remains a leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have emerged as a promising therapy for NSCLC but only benefit a subset of patients. In this issue of the JCI, Jiao et al. revealed that acetyl-CoA acetyltransferase 1 (ACAT1) limited the efficacy of ICIs in NSCLC by impeding tertiary lymphoid structures (TLS) in the tumor mic…